Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies

Ki67 index is now an essential part of classification of pancreatic neuroendocrine tumors. However, its adaptation into daily practice has been fraught with challenges related to counting methodology. In this study, three reviewers used four counting methodologies to calculate Ki67 index in 68 well-differentiated pancreatic neuroendocrine tumors: (1) ‘eye-ball’ estimation, which has been advocated as reliable and is widely used; (2) automated counting by image analyzer; (3) manual eye-counting (eye under a microscope without a grid); and (4) manual count of camera-captured/printed image. Pearson’s correlation (R) was used to measure pair-wise correlation among three reviewers using all four methodologies. Average level of agreement was calculated using mean of R values. The results showed that: (1) ‘eye-balling’ was least expensive and fastest (average time <1 min) but had poor reliability and reproducibility. (2) Automated count was the most expensive and least practical with major impact on turnaround time (limited by machine and personnel accessibility), and, more importantly, had inaccuracies in overcounting unwanted material. (3) Manual eye count had no additional cost, averaged 6 min, but proved impractical and poorly reproducible. (4) Camera-captured/printed image was most reliable, had highest reproducibility, but took longer than ‘eye-balling’. In conclusion, based on its comparatively low cost/benefit ratio and reproducibility, camera-captured/printed image appears to be the most practical for calculating Ki67 index. Although automated counting is generally advertised as the gold standard for index calculation, in this study it was not as accurate or cost-effective as camera-captured/printed image and was highly operator-dependent. ‘Eye-balling’ produces highly inaccurate and unreliable results, and is not recommended for routine use.

[1]  J. Polak,et al.  Endocrine tumors of the pancreas , 1988 .

[2]  B. Eriksson,et al.  Endocrine tumours of the pancreas. , 2005, Best practice & research. Clinical gastroenterology.

[3]  A. Krasinskas,et al.  Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. , 2012, American journal of clinical pathology.

[4]  Laura H. Tang,et al.  Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification , 2011, The American journal of surgical pathology.

[5]  N. Adsay,et al.  Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies , 2014, Endocrine Pathology.

[6]  A. Benson,et al.  The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum , 2010, Pancreas.

[7]  Laura H. Tang,et al.  Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2012, The American journal of surgical pathology.

[8]  C. Cohen,et al.  Phosphohistone H3 and Ki-67 Labeling Indices in Cytologic Specimens from Well-Differentiated Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas: A Comparative Analysis Using Automated Image Cytometry , 2013, Acta Cytologica.

[9]  Toby C. Cornish,et al.  Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate , 2013, The American journal of surgical pathology.

[10]  Manal M. Hassan,et al.  The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum , 2010, Pancreas.

[11]  B. Weinhold Epigenetics: The Science of Change , 2006, Virchows Archiv.

[12]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[13]  D. Allison,et al.  Endocrine tumors of the pancreas. , 1989, Radiologic clinics of North America.

[14]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[15]  M. Salto‐Tellez,et al.  Computer‐assisted pathological immunohistochemistry scoring is more time‐effective than conventional scoring, but provides no analytical advantage , 2010, Histopathology.

[16]  D. Klimstra Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. , 2013, Seminars in oncology.

[17]  G. Baron,et al.  Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors , 2009, Modern Pathology.

[18]  P. Schnabel,et al.  Grading neuroendokriner Tumoren , 2016, Der Pathologe.

[19]  V. Adsay Ki67 Labeling Index in Neuroendocrine Tumors of the Gastrointestinal and Pancreatobiliary Tract: To Count or Not to Count Is Not the Question, But Rather How to Count , 2012, The American journal of surgical pathology.

[20]  M. Washington,et al.  Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set , 2010, The American journal of surgical pathology.

[21]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Compton,et al.  Exocrine and Endocrine Pancreas , 2012 .

[23]  A. Scarpa,et al.  Pathology and Genetics , 2010 .